SCHEMBL8187802

SCHEMBL8187802

CCOC(=O)Cc1cn(Cc2cccc(Br)c2)c2ccccc12

nearest known ligand 0.59

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FNTA P49354 3/20 0.59
FNTB P49356 3/20 0.59
LMNA P02545 4/20 0.54
ALDH1A1 P00352 3/20 0.54
CYP19A1 P11511 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.48
NPSR1 Q6W5P4 2/20 0.48
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
F2RL3 Q96RI0 1/20 0.46
CHRNB2 P17787 1/20 0.46
CHRNA7 P36544 1/20 0.46
CHRNA4 P43681 1/20 0.46
ICMT O60725 2/20 0.45
CREBBP Q92793 1/20 0.45
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8166587 0.88 CHRNB2 (0.60) FNTAFNTBLMNAALDH1A1L3MBTL1
SCHEMBL8175090 0.88 FNTA (0.57) FNTAFNTBLMNAALDH1A1L3MBTL1
SCHEMBL8173457 0.86 PLA2G2A (0.55) LMNAALDH1A1L3MBTL1SMN1; SMN2NPSR1
SCHEMBL13931024 0.85 LMNA (0.54) FNTAFNTBLMNAALDH1A1L3MBTL1
SCHEMBL13931030 0.84 LMNA (0.53) FNTAFNTBLMNAALDH1A1L3MBTL1
SCHEMBL13931031 0.84 LMNA (0.53) FNTAFNTBLMNAALDH1A1L3MBTL1
SCHEMBL8187845 0.83 ICMT (0.49) FNTAFNTBCYP19A1ICMT
SCHEMBL8181059 0.82 CHRNB2 (0.58) FNTAFNTBLMNAALDH1A1L3MBTL1
SCHEMBL13931087 0.80 L3MBTL1 (0.45) FNTAFNTBLMNAALDH1A1L3MBTL1
SCHEMBL13931034 0.80 ALDH1A1 (0.50) FNTAFNTBLMNAALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 US disclosed
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-02-19 US disclosed
WO-2008100867-A2 NOVEL INHIBITORS HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2008-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090047246-A1 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION EIF2AK2, HAVCR2, HCCS FNTA 710/4885FNTB 730/4885LMNA 2969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.